Furthermore, the immunohistochemical results suggested that the synergistic therapy with PLCG2 knockdown and anti-PD-1 could reverse tumor immune escape by inhibiting the expression of immune checkpoints and induce CD8+ T cells infiltration to transform the tumor microenvironment from "cold" to "hot". Here, PDCD1 is linked to neoplasm.